Sign up to access all valuation multiples
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
2005
6.2K+
LTM Revenue $682M
LTM EBITDA $144M
$5.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Laurus Labs has a last 12-month revenue (LTM) of $682M and a last 12-month EBITDA of $144M.
In the most recent fiscal year, Laurus Labs achieved revenue of $631M and an EBITDA of $128M.
Laurus Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Laurus Labs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $682M | XXX | $631M | XXX | XXX | XXX |
| Gross Profit | $382M | XXX | $340M | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $144M | XXX | $128M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $96.0M | XXX | $71.6M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $54.2M | XXX | $41.0M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $297M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Laurus Labs's stock price is INR 856 (or $10).
Laurus Labs has current market cap of INR 462B (or $5.3B), and EV of INR 489B (or $5.6B).
See Laurus Labs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.6B | $5.3B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Laurus Labs has market cap of $5.3B and EV of $5.6B.
Laurus Labs's trades at 9.1x EV/Revenue multiple, and 47.1x EV/EBITDA.
Equity research analysts estimate Laurus Labs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Laurus Labs has a P/E ratio of 97.8x.
See valuation multiples for Laurus Labs and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV (current) | $5.6B | XXX | $5.6B | XXX | XXX | XXX |
| EV/Revenue | 8.2x | XXX | 9.1x | XXX | XXX | XXX |
| EV/EBITDA | 38.9x | XXX | 47.1x | XXX | XXX | XXX |
| EV/EBIT | 58.3x | XXX | 86.1x | XXX | XXX | XXX |
| EV/Gross Profit | 14.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 97.8x | XXX | 149.7x | XXX | XXX | XXX |
| EV/FCF | 731.0x | XXX | -1496.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLaurus Labs's last 12 month revenue growth is 16%
Laurus Labs's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $44K for the same period.
Laurus Labs's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Laurus Labs's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Laurus Labs and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 34% | XXX | 32% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Laurus Labs acquired XXX companies to date.
Last acquisition by Laurus Labs was XXXXXXXX, XXXXX XXXXX XXXXXX . Laurus Labs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Laurus Labs founded? | Laurus Labs was founded in 2005. |
| Where is Laurus Labs headquartered? | Laurus Labs is headquartered in India. |
| How many employees does Laurus Labs have? | As of today, Laurus Labs has 6.2K+ employees. |
| Who is the CEO of Laurus Labs? | Laurus Labs's CEO is Dr. Satyanarayana Chava. |
| Is Laurus Labs publicy listed? | Yes, Laurus Labs is a public company listed on BOM. |
| What is the stock symbol of Laurus Labs? | Laurus Labs trades under 540222 ticker. |
| When did Laurus Labs go public? | Laurus Labs went public in 2016. |
| Who are competitors of Laurus Labs? | Similar companies to Laurus Labs include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Laurus Labs? | Laurus Labs's current market cap is $5.3B |
| What is the current revenue of Laurus Labs? | Laurus Labs's last 12 months revenue is $682M. |
| What is the current revenue growth of Laurus Labs? | Laurus Labs revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Laurus Labs? | Current revenue multiple of Laurus Labs is 8.2x. |
| Is Laurus Labs profitable? | Yes, Laurus Labs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Laurus Labs? | Laurus Labs's last 12 months EBITDA is $144M. |
| What is Laurus Labs's EBITDA margin? | Laurus Labs's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Laurus Labs? | Current EBITDA multiple of Laurus Labs is 38.9x. |
| What is the current FCF of Laurus Labs? | Laurus Labs's last 12 months FCF is $7.7M. |
| What is Laurus Labs's FCF margin? | Laurus Labs's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Laurus Labs? | Current FCF multiple of Laurus Labs is 731.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
